Background and aims: International research indicates that injectable opioid agonist treatment (iOAT) is a valuable, patient-centred supplement to established treatment options. However, limited information exists on contextual factors that may support or hinder iOAT implementation and sustainability. This review aims to address this gap by examining studies on iOAT with hydromorphone and diacetylmorphine, focusing on potential barriers and facilitators.
Methodology: A systematic literature search was conducted in the MEDLINE and PsycInfo databases (via Ovid) from inception to March 2024, supplemented by a comprehensive grey literature search. No restrictions were applied regarding publication type, year, or geographic location. Articles were independently screened by two reviewers. Eligible articles described the feasibility, implementation, and/or evaluation of iOAT in one or more countries, presenting perspectives on receiving, administering, or governing iOAT.
Results: Forty-five articles were selected fo